Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.
Fiche du document
2004
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00262-003-0473-9
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/14704832
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0340-7004, 0340-7004[linking]
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9D31B462B0D58
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Communicable diseases--Vaccination Preventive inoculation Inoculation Controlled clinical trials Randomized clinical trials Trials, Clinical Patient trials of new treatments Preventive inoculation Diseases--VaccinationCiter ce document
P. Romero et al., « Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. », Serveur académique Lausannois, ID : 10.1007/s00262-003-0473-9
Métriques
Partage / Export
Résumé
Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.